Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)

被引：0

作者：

Liu, Xiufeng ^{[1
]}

Lu, Yinying ^{[2
]}

Zhou, Weiping ^{[3
]}

Peng, Tao ^{[4
]}

Zhou, Jie ^{[5
]}

Bi, Huaqiang ^{[6
]}

Xia, Feng ^{[6
]}

Chen, Xiaoping ^{[7
]}

机构：

[1] Jinling Hosp, PLA Canc Ctr, Dept Med Oncol, Nanjing, Peoples R China

[2] Peoples Liberat Army Gen Hosp, Comprehens Liver Canc Ctr, Med Ctr 5, Beijing, Peoples R China

[3] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp, Dept Hepat Surg 3, Shanghai, Peoples R China

[4] Guangxi Med Univ, Affiliated Hosp 1, Hepatobiliary Surg Dept, Nanning, Peoples R China

[5] Southern Med Univ, Nanfang Hosp, Dept Gen Surg, Div Hepatobiliopancreat Surg & Liver Transplantat, Guangzhou, Peoples R China

[6] Army Med Univ, Hosp 1, Dept Hepatobiliary Surg, Chongqing, Peoples R China

[7] Huazhong Univ Sci & Technol, Tongji Hosp, Tongji Med Coll, Dept Hepatobiliary Surg, Wuhan, Peoples R China

来源：

LIVER CANCER | 2024年 / 13卷 / 04期

关键词：

Hepatocellular carcinoma; Immunotherapy; Combination therapy; Immune checkpoint inhibitors; Multidisciplinary team; Consensus; TENOFOVIR DISOPROXIL FUMARATE; OPEN-LABEL; DOUBLE-BLIND; CONVERSION THERAPY; SINTILIMAB PLUS; SORAFENIB; PHASE-3; IMMUNOTHERAPY; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.1159/000535496

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background: Immune checkpoint inhibitor (ICI)-based combination therapy modalities for hepatocellular carcinoma (HCC) have achieved significant efficacy in clinical research and practice and have become the mainstay for the treatment of unresectable HCC. Summary: To better help clinicians use combination immunotherapy drugs and regimens rationally, effectively, and safely, the editorial board facilitated a discussion with multidisciplinary experts in the field, adopted the "Delphi" consensus formation method, and finally revised and completed the "Chinese Multidisciplinary Expert Consensus on the Immune Checkpoint Inhibitors (ICIs)-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)" on the basis of the 2021 edition. Key Messages: This consensus primarily focuses on the principles and methods of clinical practice of combination therapy based on ICIs, aiming to summarize the recommendations for clinical application based on the latest research and expert experience and provide application guidance for clinicians.

引用

页码：355 / 375

页数：21

共 50 条

[1] Introduction of the Chinese expert consensus on postoperative adjuvant therapy for hepatocellular carcinoma (2023 Edition)
Zhang, Haibin
HEPATOMA RESEARCH, 2024, 10
[2] VIRAL ETIOLOGY DETERMINES OUTCOMES OF IMMUNE CHECKPOINT INHIBITOR-BASED COMBINATION THERAPY FOR UNRESECTABLE HEPATOCELLULAR CARCINOMA
Wu, Chi-Jung
Lee, Pei-Chang
Hung, Ya-Wen
Lee, Chieh-Ju
Chi, Chen-Ta
Lee, I-Cheng
Hou, Ming-Chih
Huang, Yi-Hsiang
HEPATOLOGY, 2022, 76 : S1376 - S1376
[3] Chinese expert consensus on the multidisciplinary management of pneumonitis associated with immune checkpoint inhibitor
Wang, Wenxian
Wang, Qian
Xu, Chunwei
Li, Ziming
Song, Zhengbo
Zhang, Yongchang
Cai, Xiuyu
Zhang, Shirong
Lian, Bin
Li, Wen
Liu, Anwen
Zhan, Ping
Liu, Hongbing
Lv, Tangfeng
Miao, Liyun
Min, Lingfeng
Chen, Yu
Yuan, Jingping
Wang, Feng
Jiang, Zhansheng
Lin, Gen
Pu, Xingxiang
Rao, Chuangzhou
Lv, Dongqing
Yu, Zongyang
Li, Xiaoyan
Tang, Chuanhao
Zhou, Chengzhi
Xie, Congying
Zhang, Junping
Guo, Hui
Chu, Qian
Meng, Rui
Wu, Jingxun
Zhang, Rui
Wang, Liping
Zhu, Youcai
Hu, Xiao
Xie, Yanru
Lin, Xinqing
Cai, Jing
Lan, Fen
Feng, Huijing
Wang, Lin
Yao, Wang
Shi, Xuefei
Huang, Jianhui
Chen, Huafei
Zhang, Yinbin
Sun, Pingli
THORACIC CANCER, 2022, 13 (23) : 3420 - 3430
[4] Extending inflamed-class signature to predict immune checkpoint inhibitor-based combination therapy in hepatocellular carcinoma
You, Wenhua
Hu, Chupeng
Zhao, Mengya
Zhang, Yuhan
Lu, Jinying
Huang, Yedi
Li, Ling
Chen, Yun
GUT, 2024,
[5] Theoretic strategy for immune checkpoint inhibitor-based combination therapy
Chamoto, Kenji
Hung, Mien-Chie
CANCER SCIENCE, 2022, 113 : 1247 - 1247
[6] Predictive Biomarkers of Immune Checkpoint Inhibitor-Based Mono- and Combination Therapies for Hepatocellular Carcinoma
Jeng, Long-Bin
Wang, John
Teng, Chiao-Fang
JOURNAL OF CANCER, 2024, 15 (02): : 484 - 493
[7] Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)
Sun, Hui-Chuan
Zhou, Jian
Wang, Zheng
Liu, Xiufeng
Xie, Qing
Jia, Weidong
Zhao, Ming
Bi, Xinyu
Li, Gong
Bai, Xueli
Ji, Yuan
Xu, Li
Zhu, Xiao-Dong
Bai, Dousheng
Chen, Yajin
Chen, Yongjun
Dai, Chaoliu
Guo, Rongping
Guo, Wenzhi
Hao, Chunyi
Huang, Tao
Huang, Zhiyong
Li, Deyu
Li, Gang
Li, Tao
Li, Xiangcheng
Liang, Xiao
Liu, Jingfeng
Liu, Fubao
Lu, Shichun
Lu, Zheng
Lv, Weifu
Mao, Yilei
Shao, Guoliang
Shi, Yinghong
Song, Tianqiang
Tan, Guang
Tang, Yunqiang
Tao, Kaishan
Wan, Chidan
Wang, Guangyi
Wang, Lu
Wang, Shunxiang
Wen, Tianfu
Xing, Baocai
Xiang, Bangde
Yan, Sheng
Yang, Dinghua
Yin, Guowen
Yin, Tao
HEPATOBILIARY SURGERY AND NUTRITION, 2022, 11 (02) : 227 - +
[8] Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal Cancer: An Overview
Li, Jingjing
Xu, Xuanfu
INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2023, 16 : 1527 - 1540
[9] Marker-guided immune checkpoint inhibitor-based combination therapy
Hung, Mien-Chie
CANCER SCIENCE, 2022, 113 : 1248 - 1248
[10] Chinese Expert Consensus on the Whole-Course Management of Hepatocellular Carcinoma (2023 Edition)
Yang, Yu
Sun, Juxian
Cai, Jianqiang
Chen, Minshan
Dai, Chaoliu
Wen, Tianfu
Xia, Jinglin
Ying, Mingang
Zhang, Zhiwei
Zhang, Xuewen
Fang, Chihua
Shen, Feng
An, Ping
Cai, Qingxian
Cao, Jingyu
Zeng, Zhen
Chen, Gang
Chen, Juan
Chen, Ping
Chen, Yongshun
Shan, Yunfeng
Dang, Shuangsuo
Guo, Wei-Xing
He, Jiefeng
Hu, Heping
Huang, Bin
Jia, Weidong
Jiang, Kexiang
Jin, Yan
Jin, Yongdong
Jin, Yun
Li, Gong
Liang, Yun
Liu, Enyu
Liu, Hao
Peng, Wei
Peng, Zhenwei
Peng, Zhiyi
Qian, Yeben
Ren, Wanhua
Shi, Jie
Song, Yusheng
Tao, Min
Tie, Jun
Wan, Xueying
Wang, Bin
Wang, Jin
Wang, Kai
Wang, Kang
Wang, Xin
LIVER CANCER, 2024,

← 1 2 3 4 5 →